CymaBay Therapeutics, Inc. Company Review & Valuation
About CymaBay Therapeutics, Inc.
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases.
Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.
The company also develops arhalofenate, which has completed five Phase II clinical trials for the treatment of patients with gout; and MBX-2982, an oral G-protein coupled receptor agonist that has completed one Phase II clinical trial for therapeutic indications.
It has licensing agreement with Kowa Pharmaceuticals America, Inc.
for the development and commercialization of arhalofenate in the United States; and Janssen Pharmaceuticals, Inc.
to develop and discover undisclosed metabolic disease target agonists for the treatment of type II diabetes and other disorders, as well as a license and development agreement with DiaTex, Inc.
to develop and commercialize therapeutic products comrprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases.
The company was formerly known as Metabolex, Inc.
CymaBay Therapeutics, Inc.
was incorporated in 1988 and is headquartered in Newark, California.